Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Net Income: 2011-2025

Historic Net Income for Ani Pharmaceuticals (ANIP) over the last 15 years, with Sep 2025 value amounting to $26.6 million.

  • Ani Pharmaceuticals' Net Income rose 210.07% to $26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.5 million, marking a year-over-year increase of 671.57%. This contributed to the annual value of -$18.5 million for FY2024, which is 198.63% down from last year.
  • Per Ani Pharmaceuticals' latest filing, its Net Income stood at $26.6 million for Q3 2025, which was up 212.02% from $8.5 million recorded in Q2 2025.
  • Ani Pharmaceuticals' Net Income's 5-year high stood at $26.6 million during Q3 2025, with a 5-year trough of -$24.2 million in Q3 2024.
  • Its 3-year average for Net Income is $4.6 million, with a median of $6.2 million in 2023.
  • Its Net Income has fluctuated over the past 5 years, first plummeted by 18,372.73% in 2022, then skyrocketed by 1,135.21% in 2024.
  • Over the past 5 years, Ani Pharmaceuticals' Net Income (MRQ) stood at -$24.1 million in 2021, then skyrocketed by 82.35% to -$4.3 million in 2022, then surged by 127.12% to $1.2 million in 2023, then crashed by 989.70% to -$10.3 million in 2024, then surged by 358.86% to $26.6 million in 2025.
  • Its Net Income stands at $26.6 million for Q3 2025, versus $8.5 million for Q2 2025 and $15.7 million for Q1 2025.